Intai Technology (鐿鈦科技) continues to anchor its growth strategy on the high-margin medical device sector while actively expanding into high-growth applications, including medical surgical robotics, critical components for semiconductor equipment, and high-frequency microwave switches. Among these, its microwave switches engineered for AI servers and silicon photonics high-speed testing have successfully cleared customer validation and entered the quasi-mass production stage, positioning this segment as the company's primary operational growth engine.

Financial Performance & Optimized Product Mix

For the first quarter of 2026, Intai reported a consolidated revenue of NT$623 million, representing a 7.74% increase quarter-on-quarter (QoQ) and a 1.75% increase year-on-year (YoY). Benefiting from an increased revenue contribution from high-margin medical devices, an optimized product portfolio, and manufacturing process efficiencies, the company’s single-quarter gross margin held at a premium level of 43%. Operating income reached NT$72.16 million, yielding an operating margin of 12%. Net profit after tax stood at NT$78.87 million, delivering an Earnings Per Share (EPS) of NT$1.29.

Deep Penetration into the Global Medical Supply Chain

Intai noted that its product architecture is steadily shifting toward high-margin medical applications. The revenue share of medical devices has risen from 68% in 2021 to 76% in Q1 2026, consistently remaining above the 75% threshold in recent years. Due to their long product lifecycles, high regulatory validation barriers, and strong customer stickiness, these medical products significantly enhance the company's earnings quality and operational stability.

The company's medical device revenue grew from NT$1.35 billion in 2021 to NT$1.84 billion in 2025, representing a Compound Annual Growth Rate (CAGR) of approximately 8%. This underscores Intai's competitive advantages in client acquisition, product validation, and mass-production execution. Geographically, the Americas market accounted for approximately 85% of its 2025 medical device revenue, demonstrating Intai's successful integration into the world's largest medical device market and supply chain infrastructure.

Multi-Domain Clinical Applications

Currently, Intai’s medical portfolio spans cardiovascular surgery, minimally invasive surgery (MIS), endoscopy, diagnostic testing, and chronic disease management. Specific product lines include coronary stents, catheters, linear cutters/staplers, robotic surgical instruments, disposable endoscopes, biopsy tools, and continuous glucose monitoring (CGM) systems. Management stated that global population aging, the rising prevalence of chronic conditions, and the increasing penetration of minimally invasive and robotic surgeries will continue to drive robust global demand for high-end medical devices.

Semiconductor and Advanced On-Shore Processing Assets

Beyond the healthcare market, Intai is aggressively deploying into industrial sectors, with applications spanning aerospace, automotive, robotics, semiconductor equipment, and unmanned aerial vehicles (UAVs). The company has successfully penetrated the advanced semiconductor process supply chain, providing critical components utilized in wafer cleaning equipment, vacuum and gas delivery systems, and ion diffusion process equipment.

Vice President Chen Ching-feng noted that as AI and data center demands escalate, global semiconductor foundries are expanding their capital expenditures. Intai’s entry into the advanced process supply chain will optimize its product mix, increase the proportion of high-value-added components, and further elevate gross margins and profitability. He indicated that current shipments primarily target front-end cleaning processes, with plans to expand into mid- and back-end process equipment in the future.

High-Frequency Communication & Silicon Photonics

In the high-frequency communication sector, Intai possesses independent design and manufacturing capabilities for high-frequency microwave switches operating at 43GHz, 53GHz, 67GHz, and 110GHz. The company currently holds 7 invention patents, with an additional 3 patents pending. These products target AI servers, high-speed communication testing, defense, and satellite communication markets.

Intai's microwave switches have successfully completed customer validation for AI servers and silicon photonics high-speed testing, moving into the quasi-mass production phase. Its core clientele includes the world's top three analytical instrument manufacturers, alongside major semiconductor foundries and AI IC design houses. Driven by the sustained growth of AI high-performance computing (HPC) and high-frequency data transmission, this segment possesses strong forward operational momentum.

Surgical Robotics Pipeline and Capacity Outlook

Addressing shareholder interest in its medical surgical robotics pipeline, Intai stated that it is currently collaborating with a key client on product validation for a next-generation surgical platform. Pronounced milestone progress is anticipated in H2 2026, with initial, low-volume revenue contributions expected to manifest by 2027 at the earliest. Furthermore, the company's current overall capacity utilization rate stands at approximately 80%. Future production expansion will be centered at its Houli facility (后科廠), and revenue growth is expected to scale sequentially as these new product lines transition into mass production.

Resource:鐿鈦佈局手術機器人，H2可望有明顯進展